ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Peptidream Inc.

Business Summary

PeptiDream Inc. engages in the biopharmaceutical business that includes research and development of non standard peptide therapeutics. It produces stable, and potent non-standard macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS). The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan.

Financial Highlights

Dec 2019 JPYUSD
Revenue2,074.67M19.03M
Gross Profit661.06M6.06M
Operating income-1,774.33M-16.27M
Income before tax-1,413.07M-12.96M
Net income-976.92M-8.96M
EBITDA-1,261.79M-11.57M
Diluted EPS-7.80-0.07
Dividends Per Share00
Total Assets17,817.34M163.95M
Total liabilities839.05M7.72M
Total equity16,978.28M156.22M
Operating cash flow241.98M2.21M
Currency in JPYCurrency in USD

Historical Data

 Jun 2015Jun 2016Jun 2017Jun 2018Dec 2019
Revenue 2,474.49M 4,327.87M 4,895.74M 6,426.89M 2,074.67M
Gross Profit 1,752.47M 3,241.08M 3,530.02M 4,648.26M 661.06M
Operating income 1,391.12M 2,548.08M 2,490.41M 2,978.48M -1,774.33M
Income before tax 1,493.37M 2,365.81M 2,624.15M 3,151.73M -1,413.07M
Net income 1,004.16M 1,581.28M 1,890.75M 2,335.21M -976.92M
EBITDA 1,494.19M 2,691.08M 2,685.28M 3,491.82M -1,261.79M
Diluted EPS 7.83 12.26 14.56 17.79 -7.80
Dividends Per Share 0 0 0 0 0
Total Assets 7,738.44M 11,956.40M 13,628.45M 16,512.83M 17,817.34M
Total liabilities 826.01M 1,713.64M 1,447.65M 1,804.11M 839.05M
Total equity 6,912.43M 10,242.75M 12,180.80M 14,708.71M 16,978.28M
Operating cash flow 1,386.14M 1,533.05M 1,530.77M 1,022.71M 241.98M
 Jun 2015Jun 2016Jun 2017Jun 2018Dec 2019
Revenue 21.58M 37.08M 44.87M 58.24M 19.03M
Gross Profit 15.28M 27.77M 32.35M 42.12M 6.06M
Operating income 12.13M 21.83M 22.82M 26.99M -16.27M
Income before tax 13.02M 20.27M 24.05M 28.56M -12.96M
Net income 8.76M 13.54M 17.33M 21.16M -8.96M
EBITDA 13.03M 23.05M 24.61M 31.64M -11.57M
Diluted EPS 0.06 0.10 0.13 0.16 -0.07
Dividends Per Share 0 0 0 0 0
Total Assets 63.24M 116.54M 121.29M 149.07M 163.95M
Total liabilities 6.75M 16.70M 12.88M 16.28M 7.72M
Total equity 56.49M 99.84M 108.40M 132.79M 156.22M
Operating cash flow 12.09M 13.13M 14.03M 9.26M 2.21M

Valuation Measures

Dec 2019
PER--
ROA-5.69%
ROE-6.16%
Operating margin-85.52%
Profit margin-47.08%

Key executives

  • President & Representative Director: Patrick Crawford Reid
  • Director, Manager-Research & Development: Keiichi Masuya
  • Manager-Public & Investor Relations: Toshiyuki Iwata

Shareholders

  • KUBOTA KIICHI (11.2%)
  • SUGA HIROAKI (8.7%)
  • J.O. Hambro Capital Management Ltd. (7.8%)
  • JPMorgan Asset Management (Japan) Ltd. (4.1%)
  • Asset Management One Co., Ltd. (4.1%)
  • REID PATRICK C (3.6%)
  • BlackRock Fund Advisors (3.0%)
  • Nomura Asset Management Co., Ltd. (2.7%)
  • Invesco Advisers, Inc. (2.3%)
  • The Vanguard Group, Inc. (1.9%)

Contact Details

Related Companies

  • Peptidream Board Incentive Plan
  • Peptidream Employee Incentive Plan
  • PharmaDesign, Inc. (Japan) /Pharma Research Bus/
  • PharmaDesign, Inc. (Japan)

Competitors

  • Aileron Therapeutics, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bicycle Therapeutics Plc Sponsored ADR
  • MorphoSys AG
  • Protagonist Therapeutics, Inc.
  • UCB S.A.
Last Updated on 15 Jan, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more